Afatinib

Indications & Dose:

First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor (EGFR)

DOSAGE

ORALLY 

40 mg orally, once daily  

Renal impairment: 30 mg orally, once daily

Contraindications:

None

Side Effects:

Most common :diarrhea, rash/acneiform dermatitis, stomatitis, paronychia, dry skin, decreased appetite, nausea, vomiting, pruritus 

Cautions:

Precautions:

Diarrhea: Diarrhea may result in dehydration and renal failure. Withhold  for severe and prolonged diarrhea not responsive to antidiarrheal agents. 

Bullous and exfoliative skin disorders: Withhold  for severe and prolonged cutaneous reactions. 

Interstitial lung disease (ILD):  worsening of pulmonary symptoms.Discontinue  if ILD is diagnosed. 

Hepatic toxicity: Withhold or discontinue  for severe or worsening liver tests.

Keratitis: Withhold  for keratitis evaluation. Withhold or discontinue  for confirmed ulcerative

keratitis. 

Embryo-fetal toxicity:Potential risk to the fetus and to use effective contraception.

Interaction:

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: